Key Takeaways The CDC revised RSV guidance to include high-risk individuals aged 50-59, expanding eligibility. The expanded guidance increases Moderna's addressable market for its RSV vaccine, mResvia. Moderna trails GSK and Pfizer, but broader access could help close the gap in future RSV seasons.Shares of Moderna (MRNA) rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new recommendations for the use of RSV vaccines in the upcoming respiratory virus seaso ...